December 2, 2020 at 17:00 UK
Speaker: Dr. Peter Guterstam
Product Manager, Next Generation Resins and Technologies, Cytiva
As more AAV-based gene therapies move towards the clinic, there is a growing need for scalable and cost-effective production processes that maintain virus quality. In downstream processing, the capture chromatography step is a bottleneck. To address the need for higher productivity, we are developing a novel fiber technology, Fibro, which uses a proprietary structure that overcomes the diffusional and flow limitations of packed- bed chromatography. The fiber structure is highly open to facilitate mass transfer without diffusion, as with membrane and monolith technologies. Unlike those options, the Fibro structure provides a large surface area resulting from an additive manufacturing process.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
